# NCT05411081 (NCT05411081)

> Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05411081
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Metastatic Papillary Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8
- Interventions: Atezolizumab; Biospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging
- Enrollment: 200
- Primary outcome: Progression free survival

## Commentary we found

- X threads: 30
- YouTube: 20
- Podcasts: 9
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct05411081

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05411081", "email": "<work email>"}; the inbox owner confirms by the emailed link.